News | April 28, 2024
Apollo HealthCo to raise Rs. 2,475 crore from Advent International
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Breakthrough Therapy designation for pain associated with DPN granted by FDA
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The company plans to add 1700 beds by FY27 through the organic route
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
These digital avenues have not only revolutionized patient care but also opened up new opportunities for HCPs to build thought leadership in their respective fields
Subscribe To Our Newsletter & Stay Updated
